Mirum Pharmaceuticals Q3 net product sales surge, outlook raised

Mirum Pharmaceuticals

Tue 21:11

Overview
US rare disease drugmaker's Q3 net product sales rose yr/yr to $185.7 mln
Company posted Q3 net loss of $40.77 mln amid higher operating expenses
Full-year 2026 net product sales guidance raised to $715 mln-$720 mln

Outlook
Mirum raises 2026 net product sales guidance to $715 mln-$720 mln

Result Drivers
LIVMARLI SALES GROWTH - Co said Q3 LIVMARLI net product sales rose 45% yr/yr, driven by expansion into additional rare cholestatic liver diseases
BILE ACID MEDICINES - Q3 Bile Acid Medicines net product sales grew 28% yr/yr, reflecting increased demand for CHOLBAM and CTEXLI
ATEBRIOZ APPROVAL AND LAUNCH - Co received US FDA approval and launched ATEBRIOZ for FOP, contributing to commercial momentum

Company press release: ID:nBw9jpRQra

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Sales
 
$185.72 mln
 
Q3 Loss Per Share
 
$0.87
 
Q3 Net Loss
 
$40.77 mln
 
Q3 Operating Expenses
 
$245.47 mln
 
Q3 Operating Income
 
-$59.75 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Mirum Pharmaceuticals, Inc. is $153.00, about 78.4% above its November 2 closing price of $85.74

Reuters Recommended Reads
Nov 3 - Rhythm Pharma Q3 net loss narrower than estimated on IMCIVREE demand
Nov 2 - Travere Q3 product sales nearly double on FILSPARI growth
Nov 2 - Tempus AI Q3 revenue slightly beats estimates; raises guidance

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)